KALV - KalVista Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.00
+1.74 (+10.70%)
At close: 4:00PM EDT

18.30 +0.30 (1.67%)
After hours: 7:46PM EDT

Stock chart is not supported by your current browser
Previous Close16.26
Open16.75
Bid18.15 x 800
Ask18.88 x 1800
Day's Range16.17 - 18.16
52 Week Range6.65 - 18.90
Volume104,550
Avg. Volume58,875
Market Cap309.235M
Beta3.15
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateDec 12, 2018 - Dec 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • Barrons.com2 days ago

    3 Biotech Stocks That Big Investors Are Snatching Up

    In the last two weeks, large investors have paid more than $51 million to buy more stock in three biotech firms.

  • Business Wire7 days ago

    KalVista Pharmaceuticals Reports Fiscal First Quarter Results

    – KVD900 Phase 2 On Track to Begin in 2018 for Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema –

  • Business Wire10 days ago

    KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the closing of its previously announced underwritten public offering of 4,600,000 shares, which included the exercise in full by the underwriters of their over-allotment option to purchase 600,000 additional shares of common stock, at a price to the public of $17.00 per share. KalVista intends to use the net proceeds from this offering to fund late stage development of KVD900, including beyond anticipated Phase 3 data and a potential larger Phase 2 trial and other activities to accelerate the timeline for a new drug application, and to support accelerated development of additional hereditary angioedema (HAE) and oral diabetic macular edema (DME) programs.

  • KalVista Pharmaceuticals (KALV) Q1 Earnings Preview: What to Look Out For
    Zacks15 days ago

    KalVista Pharmaceuticals (KALV) Q1 Earnings Preview: What to Look Out For

    KalVista Pharmaceuticals (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire15 days ago

    KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be approximately $68.0 million. The offering is expected to close on September 10, 2018, subject to customary closing conditions.

  • Business Wire15 days ago

    KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, announced today that it intends to offer shares of its common stock in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day over-allotment option to purchase additional shares of its common stock offered in the public offering at the public offering price less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire25 days ago

    Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista ...

  • Business Wirelast month

    KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018, at 3:40 p.m. ET in New York, NY. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • GlobeNewswirelast month

    Kalvebod Plc - Series 2 - Full Redemption

    NYKREDIT BANK A/S Kalvebod Brygge 1-3 DK-1780 Copenhagen V Denmark. Copenhagen Stock Exchange Nikolaj Plads 6– Postbox 1040 Copenhagen 1007. Kalvebod plc 6 th Floor, Pinnacle 2 Eastpoint Business Park ...

  • Business Wire2 months ago

    KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

    – KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema –

  • GlobeNewswire3 months ago

    Kalvebod Plc - Series 2 Notice re Coll Redemption

    NYKREDIT BANK A/S Kalvebod Brygge 1-3 DK-1780 Copenhagen V Denmark. Copenhagen Stock Exchange Nikolaj Plads 6– Postbox 1040 Copenhagen 1007. Kalvebod plc 6 th Floor, Pinnacle 2 Eastpoint Business Park ...

  • GlobeNewswire3 months ago

    Recent Analysis Shows Cigna, Basic Energy Services, KalVista Pharmaceuticals, QuinStreet, Armstrong World Industries, and NMI Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, June 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cigna ...

  • Business Wire4 months ago

    KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 8, 2018, at 9:30 a.m. ET in New York, NY. A live webcast of the presentation may be accessed on the Investors section of the Company’s website at www.kalvista.com. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • Business Wire4 months ago

    KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

    “We are pleased to have developed a proprietary immunoassay to characterize the effects of our novel orally-available plasma kallikrein inhibitor, KVD900, in development for treatment of hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “Using this method, we are able to demonstrate that KVD900 protects high molecular weight kininogen from plasma kallikrein mediated cleavage in HAE and control plasma.

  • Business Wire4 months ago

    KalVista Pharmaceuticals Recognizes HAE Day

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced recognition of patient organizations from around the world holding a global awareness day for the condition hereditary angioedema .

  • Business Wire5 months ago

    KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data in support of the Company’s development activities in diabetic macular edema from an oral presentation at The Association for Research in Vision and Ophthalmology 2018 Annual Meeting in Honolulu, Hawaii.

  • Business Wire5 months ago

    KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that data in support of KalVista’s ongoing development in diabetic macular edema has been accepted for oral presentation at The Association for Research in Vision and Ophthalmology 2018 Annual Meeting on May 1, 2018 ...

  • ACCESSWIRE6 months ago

    Wired News – Sangamo Therapeutics’ Preclinical Study Data from MPS II in Vivo Genome Editing Program Published in Molecular Therapy

    Stock Monitor: KalVista Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Sangamo Therapeutics, Inc. (NASDAQ: SGMO ...

  • Business Wire6 months ago

    KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal third quarter ended January 31, 2018.

  • Business Wire7 months ago

    KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the ROTH Conference on Monday, March 12, 2018, at 2:30 p.m.

  • Business Wire9 months ago

    KalVista Pharmaceuticals Commences Two Clinical Trials

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the initiation of two clinical trials: a Phase 2 proof-of-concept clinical trial evaluating the safety, tolerability, and efficacy of KVD001 as a treatment for diabetic macular edema , as well as a Phase 1 trial ...